GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Antithrombotics; Aspirin; Vitamin K antagonists
- Indications Myocardial infarction; Pulmonary embolism; Stroke; Thromboembolism; Transient ischaemic attacks
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLORIA-AF
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Jan 2025 Results investigating the prevalence of asymptomatic atrial fibrillation (aAF) in patients with a history of stroke or an acute stroke on admission (Phase 2) published in the Pacing and Clinical Electrophysiology.
- 01 Jan 2024 Results of pooled analysis from NCT01468701, NCT01671007 and NCT01937377; evaluating the predictive ability of the 2MACE score published in the Journal of Thrombosis and Thrombolysis
- 01 Jan 2024 Results demonstrating antithrombotic effect of dabigatran and vitamin K antagonist in Patients with Atrial Fibrillation, published in the American Journal of Therapeutics.